

Event description:

The immune system weakens with age and this concept is named “immunosenescence”. Immunosenescence contributes to a reduced ability to respond to natural infections but also to develop optimal immunity following administration of some vaccines. Indeed, while vaccines against tetanus, diphtheria, pertussis and hepatitis have demonstrated immunogenicity and acceptable safety profiles in older adults, some other vaccines have only limited efficacy.

As the population of countries ages, an increasing proportion of adults are therefore at increased risk of infectious diseases including those that are preventable by vaccination. Although a number of vaccines are currently recommended for older adults, vaccination coverage in this particular group remains low.

Fortunately, novel technology has facilitated the development of new and/or improved vaccines for adults that could significantly contribute to the implementation of healthy aging strategies.

A large panel of renowned immunologists, microbiologists, vaccinologists, public health experts, infectious diseases specialists, and geriatricians will share their clinical experience with vaccine-preventable disease in older patients and explain the mechanisms of immunosenescence and the impact of immune aging on vaccination, but also provide the latest developments in vaccine science that may improve the efficacy of vaccines in this age group.

Registration fee: 80.00 Singapore dollars

For online registration, please visit website: www.isirv.org

For inquiries, email: admin@isirv-imrp.org



**4 CME Points
Accredited**



Masterclass in Vaccinology: VACCINATION AND HEALTHY AGING

**10 March 2018
12.00 - 18.15**

UPDATED VENUE

**Jubilee Ballroom, Level 4
Four Points by Sheraton, Riverview,
Singapore**

FOR HEALTHCARE PROFESSIONAL ONLY
Singapore Medical Council accredits 4 CME points for this event

Time	Module & summary of content	Speaker(s) & affiliation
12:00 - 13:20	Lunch	
13:20 - 13:30	Welcome and introduction	Gavin SMITH <i>Professor, Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore</i>
13:30 - 14:10	What is immunosenescence?	
	A healthy immune system (short summary: how immune system controls infections, innate immune response, adaptive immune response)	OOI Eng Eong <i>Professor & Deputy Director, Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore</i>
	Biological age: an immunologist perspective (definition of immunosenescence, chronological age vs biological age)	Lisa F.P. NG <i>Sr. Principal Investigator, Laboratory of Microbial Immunity, A*STAR, Singapore</i>
	Changes in the immune system associated with age (effects of age on the various compartments of the immune system)	
	Q&A	All speakers
14:10 - 15:25	Impact of immunosenescence on vaccination	
	Why vaccinate older adults (vaccines recommended in older age groups, rationale of vaccines usually recommended)	Limin WIJAYA <i>Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore</i>
	Immune response to vaccination in older adults (normal immune response to vaccination vs reduced immune response to vaccines in elderly)	
	Immunosenescence and the experience with Hepatitis A and Hepatitis B vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults)	Woo-Yun SOHN <i>South East Asia Cluster Medical Lead, GSK Vaccines</i>
	Immunosenescence and experience with influenza vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults)	Philippe BUCHY <i>Director, Scientific Affairs & Public Health, GSK Vaccines</i>
	Immunosenescence and response to inactivated and live-attenuated zoster vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults)	Michael NISSEN <i>Director, Scientific Affairs & Public Health, GSK Vaccines</i>
	Q&A	All speakers
15:25 - 15:50	Tea break	

15:50 - 16:45	How to improve the efficacy of vaccination in older adults?	
	Contribution of herd immunity to protection of older adults (principles, example of influenza vaccination of young children to provide herd immunity for older adults)	Sanjoy DATTA <i>Vice President, Clinical R&D & Medical Affairs, GSK Vaccines</i>
	Higher vaccine doses (influenza, zoster)	Philippe BUCHY <i>Director, Scientific Affairs & Public Health, GSK Vaccines</i>
	Alternative delivery routes	Béatrice LAUPÈZE <i>Sr. Mgr., Global Medical Affairs, GSK Vaccines</i>
	Adjuvants (mechanisms of action, aluminium, MF59, GSK adjuvant systems, etc.)	
	Q&A	All speakers
16:45 - 18:10	Case studies – Clinical expert's opinion (list of indicative topics that could be covered by clinicians)	
	Challenges in preventing pneumococcal disease in older adults	Doo-Ryeon CHUNG <i>Professor & Chief, Division of Infectious Diseases, Sungkyunkwan University School of Medicine, Samsung Medical Centre, South Korea</i>
	Shingles – clinical case report	LEO Yee Sin <i>Professor & Director of Institute of Infectious Disease and Epidemiology, TTSH, Singapore Clinical Director of Communicable Disease Centre, TTSH, Singapore</i>
	Tetanus, diphtheria and pertussis in older adults: what are the risks?	LEONG Hoe Nam <i>Infectious Disease Physician, Mt. Elizabeth Novena Hospital, Singapore</i>
	Influenza – Impact of influenza disease on older adults with and without particular underlying diseases	Reshma A MERCHANT <i>Assoc. Prof. & Head of Division of Geriatric Medicine, NUS, Singapore</i>
	How to improve vaccination uptake in older adults? A clinician's perspective	Hanley HO Jian An <i>Consultant of Dept. of Clinical Epidemiology, TTSH, Singapore</i>
	Q&A	All speakers
	18:10 - 18:15	Closure